Following Completion Of Pending Sale Of Kidney Care, Baxter Targets Operational Sales Growth Of 4% To 5% Annually
Portfolio Pulse from Benzinga Newsdesk
Baxter International Inc. (BAX) is targeting operational sales growth of 4% to 5% annually following the completion of its Kidney Care segment sale. The company anticipates an adjusted operating margin of approximately 16.5% for 2025, despite a 100 basis point negative impact due to stranded costs. Baxter aims to offset these costs by 2027 through cost containment initiatives and will provide further strategic and financial details at an investor conference in 2025.
August 13, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baxter International Inc. (BAX) is targeting 4% to 5% annual sales growth following the sale of its Kidney Care segment. The company expects a 16.5% adjusted operating margin for 2025, despite a 100 basis point negative impact from stranded costs. Baxter aims to offset these costs by 2027 through cost containment initiatives.
The news indicates a positive outlook for Baxter with targeted sales growth and a clear plan to manage costs. The anticipated operating margin and cost containment initiatives suggest a strategic approach to maintaining profitability, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100